Page 1

Fourth-quarter business highlights Expanding in the fast-growing pulsed field ablation (PFA) segment of the electrophysiology market • Abbott will gain leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments. • Acquisition will position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions of people live healthier lives. • Raised quarterly dividend 6.8% to 63 cents per share for 2026, reflecting growth of more than 70% since 2020. • Abbott is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends for at least 25 consecutive years. Announced agreement to acquire Exact Sciences *Organic sales growth excludes impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business. For full financial data and reconciliation of non-GAAP measures, please see our press release dated Jan. 22, 2026, available at www.abbottinvestor.com. **Excludes the impact of COVID-19 testing sales. 1. Fourth-quarter 2025 GAAP diluted EPS was $1.01. 2. Full-year 2025 GAAP diluted EPS was $3.72. 3. On a GAAP basis, fourth-quarter Abbott sales increased 4.4%. 4. On a GAAP basis, full-year Abbott sales increased 5.7%. 5. Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition related expenses, and foreign exchange, which could significantly impact Abbott’s results in accordance with GAAP. Forward-Looking Statements Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2024, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Key business units | Fourth-quarter sales Fourth-quarter and full-year 2025 results Adjusted diluted EPS $1.501 Full-year 2026 guidance5Worldwide sales Organic sales growth 6.5% to 7.5% Fourth quarter $11.5B ↑3.8 %3 ↑6.7 %4 Adjusted diluted EPS $5.55 to $5.80 Full year $44.3B ↑12 % $5.152 ↑10 %Full year Fourth quarter Medical Devices $5.7B Diagnostics $2.5B Nutrition $1.9B Established Pharmaceuticals $1.4B • CE Mark for TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ , designed to deliver both radiofrequency and PFA energy to treat patients battling atrial fibrillation. • FDA approval for Volt™ PFA System, bringing Abbott’s first PFA offering to patients in the United States. Increased dividend for 54th consecutive year Organic* sales growth for underlying base business**